ΔNp63α在恶性肿瘤中的研究进展  

Research progress of ΔNp63α in malignant tumors

作　　者：高自平 梁卫东[1] 陈虎 司莹丽 杨博 GAO Ziping;LIANG Weidong;CHEN Hu;SI Yingli;YANG Bo(Department of Cardiothoracic Surgery,the First Affiliated Hospital of Chengdu Medical College,Chengdu,Sichuan 610500,P.R.China)

机构地区：[1]成都医学院第一附属医院胸心外科,成都610500

出　　处：《华西医学》2023年第2期304-310,共7页West China Medical Journal

基　　金：成都市医学科研课题(2021078)。

摘　　要：转录因子p63起源于p53蛋白家族,由TP63基因编码。TP63基因包含两个不同的启动子,编码TAp63和ΔNp63两种蛋白,两种蛋白可经剪切产生p63α、p63β和p63δ等亚型。ΔNp63α是TP63基因的启动子之一,作为核心调控因子在表观遗传和转录水平调控基因表达。最近的研究表明,ΔNp63α表达异常可致多种恶性肿瘤发生,同时降低恶性肿瘤对放射、化学治疗的敏感性。因此,ΔNp63α可作为恶性肿瘤诊断标志物和治疗靶点。该文就ΔNp63α在恶性肿瘤中的作用机制、耐药性等最新研究进展进行了综述。Transcription factor p63 originates from p53 protein family and is encoded by TP63 gene. TP63 gene contains two different promoters encoding two proteins, TAp63 and ΔNp63, which can be cleaved to produce p63α, p63β,p63δ and some other subtypes. ΔNp63α is one of the promoters of TP63 gene and acts as a core regulatory factor to regulate gene expression at epigenetic and transcriptional levels. Recent research shows that ΔNp63α abnormal expression can lead to the occurrence of various malignant tumors and reduce the sensitivity of malignant tumors to radiotherapy and chemotherapy. Therefore, ΔNp63α can be used as a diagnostic marker and therapeutic target for malignant tumors.This article reviews the latest research progress of ΔNp63α in the mechanism and drug resistance in malignant tumors.

关 键 词：ΔNp63α 恶性肿瘤 治疗靶点 

分 类 号：R730[医药卫生—肿瘤]